NVS NVS

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

GlobeNewswire Inc. · 1d ago

Autoimmune Disease Therapeutics Market Size to Reach USD 137.85 Billion by 2035 as Biologics and Precision Medicine Drive Growth | SNS Insider

GlobeNewswire Inc. · 2d ago

Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?

The Motley Fool · 8d ago

What Is the Vanguard International Dividend Appreciation ETF (VIGI), and Who Should Buy It?

The Motley Fool · 8d ago

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

The Motley Fool · 8d ago

Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider

GlobeNewswire Inc. · 11d ago

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

GlobeNewswire Inc. · 12d ago

Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform

GlobeNewswire Inc. · 12d ago

Photodynamic Therapy Market: Durable Growth with a CAGR of 8.3% Through 2035

GlobeNewswire Inc. · 14d ago

Exploring the Cancer Metabolism-Based Therapeutics Market: Key Drivers and Challenges to $26.3 Billion Growth

GlobeNewswire Inc. · 14d ago

Dupilumab Achieves Record $11.9 Billion in Global Sales Amidst Continued Growth

GlobeNewswire Inc. · 15d ago

3 European Stocks to Carry Investors Through the Back Half of 2026

Investing.com · 16d ago

Why I Think This Vanguard ETF Will Beat the S&P 500 Over the Next 10 Years

The Motley Fool · 28d ago

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

GlobeNewswire Inc. · 36d ago

Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

Benzinga · 36d ago

Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight

GlobeNewswire Inc. · 37d ago

Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight

GlobeNewswire Inc. · 37d ago

IEFA: Why This Fund Is One of the Best International ETFs

The Motley Fool · 43d ago

Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?

The Motley Fool · 45d ago

Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight

GlobeNewswire Inc. · 45d ago

CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking

The Motley Fool · 46d ago

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

GlobeNewswire Inc. · 48d ago

Glioblastoma Multiforme Market Poised for Significant Growth at a CAGR of 13.2% During the Forecast Period (2026–2036), as Next-Generation Therapies Enter Late-Stage Development | DelveInsight

GlobeNewswire Inc. · 51d ago

Worried About Inflation? This International ETF Could Help Protect Your Portfolio

The Motley Fool · 52d ago

Tacrolimus Market Research Report 2026: Key Growth Drivers, Challenges, Future Opportunities, and Regulatory Landscape 2025-2035

GlobeNewswire Inc. · 54d ago